Safety of Intratympanic Dexamethasone to Treat Inner Ear Diseases

Moreno, Inmaculada; Belinchon, Antonio

doi:10.5005/jp-journals-10003-1425

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study done by Murphy and Daniel (2011) in animals (12 mg/kg) shows better protection when higher doses were used intratympanically [ 24 ]. On the contrary, the study done by another author stated long-term ITD did not prevent CIHL, which employed large doses for lengthy periods of time (8 mg/24 hrs) in the same cases [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intratympanic Dexamethasone Role in Hearing Protection in Cancer Patients

Gupta,

Singh,

Garg

et al. 2023

Cureus

View full text Add to dashboard Cite

Introduction The study aims to determine the role of intratympanic dexamethasone (ITD) on the hearing profile of patients with head and neck cancer post-chemoradiotherapy. Study design This study employs a prospective case-control design. Subjects and methods In total 834 patients were evaluated for eligibility. Seven hundred and eleven were excluded because they didn’t meet the inclusion criteria. A hundred cases out of 123 were diagnosed with head and neck cancer for which the treatment protocol included cisplatin concurrent to radiotherapy recruited. Before each cisplatin treatment session, ITD was injected into one ear (experimental ear) while the other ear of the same patient served as the control. Pure-tone audiometry (PTA) and distortion product otoacoustic emissions (DPOAE) test results of the baseline and follow-up examinations in the sixth and 12th weeks were compared within and between the study and control ears. Results For pure tone thresholds, significant hearing threshold change was noticed at 8 kHz in the experimental group at six weeks and at ≥ 6 kHz in the control group. At 12 weeks, high frequencies were significantly affected at ≥ 4 kHz in the control group. When the baseline was compared across the groups in the 12th week, for otoacoustic emissions, high frequencies showed a loss in the control group more compared to the experimental side (Wilcoxon signed-rank test). Conclusion ITD functions less effectively at higher frequencies because the basal turn of the cochlea is more susceptible to cisplatin ototoxicity. ITD might have potential in the reduction of cisplatin-induced hearing loss.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Our findings correlated with other studies done in small mammals [ 26 , 27 ]. There are very few studies that looked at ITD in the treatment of cisplatin-induced hearing loss cases in human beings [ 25 ]. According to Marshek et al (2014), there was a significant increase in pure tone thresholds at 8000 Hz.…”

Section: Discussionmentioning

confidence: 99%